ZA201804227B - Methods of treating cancer - Google Patents
Methods of treating cancerInfo
- Publication number
- ZA201804227B ZA201804227B ZA2018/04227A ZA201804227A ZA201804227B ZA 201804227 B ZA201804227 B ZA 201804227B ZA 2018/04227 A ZA2018/04227 A ZA 2018/04227A ZA 201804227 A ZA201804227 A ZA 201804227A ZA 201804227 B ZA201804227 B ZA 201804227B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387383P | 2015-12-24 | 2015-12-24 | |
| US201662324211P | 2016-04-18 | 2016-04-18 | |
| US201662350602P | 2016-06-15 | 2016-06-15 | |
| US201662421171P | 2016-11-11 | 2016-11-11 | |
| US201662421109P | 2016-11-11 | 2016-11-11 | |
| PCT/US2016/068459 WO2017112917A1 (en) | 2015-12-24 | 2016-12-22 | Methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201804227B true ZA201804227B (en) | 2022-07-27 |
Family
ID=59091273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2018/04227A ZA201804227B (en) | 2015-12-24 | 2018-06-22 | Methods of treating cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10912776B2 (https=) |
| EP (1) | EP3393475B1 (https=) |
| JP (1) | JP6847958B2 (https=) |
| KR (1) | KR20180103918A (https=) |
| CN (1) | CN108883107A (https=) |
| AU (1) | AU2016379425B2 (https=) |
| CA (1) | CA3009527C (https=) |
| EA (1) | EA201891509A1 (https=) |
| ES (1) | ES3017686T3 (https=) |
| IL (1) | IL260199B (https=) |
| MX (1) | MX391382B (https=) |
| WO (1) | WO2017112917A1 (https=) |
| ZA (1) | ZA201804227B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3393475B1 (en) * | 2015-12-24 | 2025-02-05 | Corvus Pharmaceuticals, Inc. | Ciforadent alone or in combination with atezolizumab for use in treating cancer |
| EP3606531A4 (en) | 2017-04-04 | 2021-04-28 | Corvus Pharmaceuticals, Inc. | METHOD OF TREATMENT OF CANCER |
| CN111163780A (zh) | 2017-07-18 | 2020-05-15 | 诺维逊生物股份有限公司 | 作为腺苷拮抗剂的杂环化合物 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| CN109293652B (zh) * | 2017-07-24 | 2021-10-22 | 四川科伦博泰生物医药股份有限公司 | 一种取代的噻唑衍生物及其用途 |
| EP3668517A4 (en) * | 2017-08-14 | 2021-02-17 | Phosphorex, Inc. | Microparticle formulations of adenosine receptor antagonists for treating cancer |
| CN109662966A (zh) * | 2017-10-16 | 2019-04-23 | 北京莱科金基因科技有限责任公司 | 伊曲茶碱在制备用于肿瘤治疗的药物中的用途 |
| CN111587113A (zh) * | 2017-11-06 | 2020-08-25 | 科尔沃斯制药股份有限公司 | 用于癌症治疗的组合疗法 |
| KR20200096921A (ko) * | 2017-11-06 | 2020-08-14 | 코버스 파마슈티칼스, 인크. | 암 치료를 위한 아데노신 경로 억제제 |
| WO2019152798A1 (en) * | 2018-02-01 | 2019-08-08 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
| EP3520782A3 (en) | 2018-02-01 | 2019-11-13 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations containing adenosine a2a receptor antagonists |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CA3100923A1 (en) | 2018-06-04 | 2019-12-12 | Exscientia Ltd | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| US12116635B2 (en) * | 2018-07-12 | 2024-10-15 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US12174192B2 (en) * | 2018-07-12 | 2024-12-24 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| AU2020208644A1 (en) | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| WO2020150676A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| KR20200105246A (ko) * | 2019-02-28 | 2020-09-07 | 한미약품 주식회사 | 아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물 |
| CN112028891B (zh) * | 2019-07-30 | 2022-07-05 | 厦门宝太生物科技股份有限公司 | 腺苷受体拮抗剂 |
| KR20220105160A (ko) * | 2019-11-26 | 2022-07-26 | 아스트라제네카 아베 | 암의 치료 방법 |
| BR112022011235A2 (pt) * | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| US20210205311A1 (en) * | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors |
| KR20230147617A (ko) * | 2021-01-21 | 2023-10-23 | 트위스트 바이오사이언스 코포레이션 | 아데노신 수용체에 관한 방법 및 조성물 |
| CN116898858B (zh) * | 2023-08-11 | 2025-09-23 | 锦州医科大学 | 一种治疗非小细胞肺癌的药物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| HK1044159A1 (zh) | 1998-12-01 | 2002-10-11 | 蛋白质设计实验室股份有限公司 | 抗γ-干扰素的人化抗体 |
| GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| US7767685B2 (en) | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| GB0906579D0 (en) | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| EP3393475B1 (en) * | 2015-12-24 | 2025-02-05 | Corvus Pharmaceuticals, Inc. | Ciforadent alone or in combination with atezolizumab for use in treating cancer |
| EP3606531A4 (en) * | 2017-04-04 | 2021-04-28 | Corvus Pharmaceuticals, Inc. | METHOD OF TREATMENT OF CANCER |
| KR20200096921A (ko) * | 2017-11-06 | 2020-08-14 | 코버스 파마슈티칼스, 인크. | 암 치료를 위한 아데노신 경로 억제제 |
| WO2019152798A1 (en) * | 2018-02-01 | 2019-08-08 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
-
2016
- 2016-12-22 EP EP16880133.0A patent/EP3393475B1/en active Active
- 2016-12-22 ES ES16880133T patent/ES3017686T3/es active Active
- 2016-12-22 CA CA3009527A patent/CA3009527C/en active Active
- 2016-12-22 US US16/065,012 patent/US10912776B2/en active Active
- 2016-12-22 EA EA201891509A patent/EA201891509A1/ru unknown
- 2016-12-22 JP JP2018533135A patent/JP6847958B2/ja active Active
- 2016-12-22 WO PCT/US2016/068459 patent/WO2017112917A1/en not_active Ceased
- 2016-12-22 CN CN201680082482.7A patent/CN108883107A/zh active Pending
- 2016-12-22 MX MX2018007765A patent/MX391382B/es unknown
- 2016-12-22 AU AU2016379425A patent/AU2016379425B2/en active Active
- 2016-12-22 KR KR1020187021355A patent/KR20180103918A/ko not_active Ceased
-
2018
- 2018-06-21 IL IL260199A patent/IL260199B/en unknown
- 2018-06-22 ZA ZA2018/04227A patent/ZA201804227B/en unknown
-
2020
- 2020-12-17 US US17/125,596 patent/US12023337B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL260199B (en) | 2022-01-01 |
| US20210154199A1 (en) | 2021-05-27 |
| WO2017112917A1 (en) | 2017-06-29 |
| EP3393475B1 (en) | 2025-02-05 |
| CA3009527A1 (en) | 2017-06-29 |
| AU2016379425A1 (en) | 2018-07-12 |
| EP3393475A1 (en) | 2018-10-31 |
| US20190076433A1 (en) | 2019-03-14 |
| JP2019503365A (ja) | 2019-02-07 |
| CN108883107A (zh) | 2018-11-23 |
| IL260199A (en) | 2018-07-31 |
| JP6847958B2 (ja) | 2021-03-24 |
| EP3393475C0 (en) | 2025-02-05 |
| KR20180103918A (ko) | 2018-09-19 |
| AU2016379425B2 (en) | 2021-11-11 |
| WO2017112917A8 (en) | 2018-07-26 |
| ES3017686T3 (en) | 2025-05-13 |
| EA201891509A1 (ru) | 2019-01-31 |
| US12023337B2 (en) | 2024-07-02 |
| MX391382B (es) | 2025-03-21 |
| US10912776B2 (en) | 2021-02-09 |
| EP3393475A4 (en) | 2019-08-14 |
| CA3009527C (en) | 2024-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL259783A (en) | Methods of treatment of malignant diseases | |
| SG11201607130RA (en) | Combination method for treatment of cancer | |
| IL259996A (en) | Combinations for cancer treatment | |
| IL256836B (en) | Methods for treating cancer using apilimod | |
| IL262342A (en) | Cancer treatment methods | |
| ZA201808258B (en) | Methods of treating pancreatic cancer | |
| IL255022A0 (en) | Cancer treatment methods | |
| EP3119390A4 (en) | Methods of treating cancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| IL253847A0 (en) | Methods of treating diseases | |
| IL255018A0 (en) | Cancer treatment methods | |
| GB201408297D0 (en) | Treatment of cancer | |
| IL255016A0 (en) | Cancer treatment methods | |
| SG11202005163PA (en) | Methods of treating cancer | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| IL269123A (en) | Methods of treating cancer | |
| GB201407837D0 (en) | Methods of cancer therapy | |
| GB201510197D0 (en) | Method of treating ovarian cancer | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201417456D0 (en) | Treatment of cancer | |
| EP3125878A4 (en) | Methods of treating breast cancer | |
| GB201512723D0 (en) | Treatment of cancer |